BACKGROUND AND OBJECTIVES:Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovascular risk and regularly receiveheparin. We tested whether antibodies to the platelet factor 4-heparin complex (PF4-H-AB) contribute to outcome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In 1255 hemodialysis patients with type 2 diabetes, the German Diabetes Dialysis Study evaluated the effect of atorvastatin (20 mg/d) versus placebo. In a post hoc analysis, the association among PF4-H-ABs, biochemistry, and prespecified, centrally adjudicated end points (combined cardiovascular end point [CVE], all-cause mortality, sudden death, myocardial infarction, stroke) was investigated. RESULTS: During 4 years, 460 patients reached the CVE; 605 died, 159 of sudden death. Myocardial infarction and stroke occurred in 199 and 97 patients, respectively. Positive PF4-H-AB status was found in 231 (18.7%) of 1236 tested patients and was associated with lower albumin, higher C-reactive protein, and arrhythmia. In a multivariate model adjusted for demographics, comorbidities, and biochemistry, PF4-H-ABs were associated with sudden death. No significant association between PF4-H-ABs and all-cause mortality, myocardial infarction, stroke, or the CVE was observed. Detecting an interaction between acetylsalicylic acid and PF4-H-ABs regarding sudden death and mortality, we found that the association between PF4-H-ABs and outcomes was restricted to patients with acetylsalicylic acid use, most likely because of indication bias. CONCLUSIONS: In hemodialysis patients who have type 2 diabetes and are treated with acetylsalicylic acid, PF4-H-ABs are associated with sudden and all-cause death. Further studies are needed to elucidate this association.
RCT Entities:
BACKGROUND AND OBJECTIVES: Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovascular risk and regularly receive heparin. We tested whether antibodies to the platelet factor 4-heparin complex (PF4-H-AB) contribute to outcome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In 1255 hemodialysis patients with type 2 diabetes, the German Diabetes Dialysis Study evaluated the effect of atorvastatin (20 mg/d) versus placebo. In a post hoc analysis, the association among PF4-H-ABs, biochemistry, and prespecified, centrally adjudicated end points (combined cardiovascular end point [CVE], all-cause mortality, sudden death, myocardial infarction, stroke) was investigated. RESULTS: During 4 years, 460 patients reached the CVE; 605 died, 159 of sudden death. Myocardial infarction and stroke occurred in 199 and 97 patients, respectively. Positive PF4-H-AB status was found in 231 (18.7%) of 1236 tested patients and was associated with lower albumin, higher C-reactive protein, and arrhythmia. In a multivariate model adjusted for demographics, comorbidities, and biochemistry, PF4-H-ABs were associated with sudden death. No significant association between PF4-H-ABs and all-cause mortality, myocardial infarction, stroke, or the CVE was observed. Detecting an interaction between acetylsalicylic acid and PF4-H-ABs regarding sudden death and mortality, we found that the association between PF4-H-ABs and outcomes was restricted to patients with acetylsalicylic acid use, most likely because of indication bias. CONCLUSIONS: In hemodialysis patients who have type 2 diabetes and are treated with acetylsalicylic acid, PF4-H-ABs are associated with sudden and all-cause death. Further studies are needed to elucidate this association.
Authors: R Taylor Williams; Lakshmi V Damaraju; Mary Ann Mascelli; Elliot S Barnathan; Robert M Califf; Maarten L Simoons; Efthymios N Deliargyris; David C Sane Journal: Circulation Date: 2003-04-21 Impact factor: 29.690
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Hans-Gernot Asmus; Walter Krämer; Karl-Wilhelm Kühn; Heinrich Kütemeyer; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: Kidney Blood Press Res Date: 2004-08-16 Impact factor: 2.687
Authors: Leila Mureebe; Richard D Coats; W Ray Silliman; Thomas A Shuster; W Kirt Nichols; Donald Silver Journal: Surgery Date: 2004-10 Impact factor: 3.982
Authors: M Carrier; M A Rodger; D Fergusson; S Doucette; M J Kovacs; J Moore; J G Kelton; G A Knoll Journal: Kidney Int Date: 2007-10-17 Impact factor: 10.612
Authors: Joseph J Naoum; Nibal R Chamoun; Mitul S Patel; Tiffany K Street; Mazen Haydar; Jean Bismuth; Hosam F El-Sayed; Mark G Davies; Alan B Lumsden; Eric K Peden Journal: Thrombosis Date: 2014-02-06